

# Application of AI in Diagnosis of Breast Cancer with Digital Mammography

Kim Eun-Kyung

Department of Radiology, Center for Clinical Imaging Data Science  
Severance Hospital  
Yonsei University, Seoul, Korea

*Severance*

# Mammography

- Screening mammography has been shown to decrease breast cancer-related mortality.
- Despite this population-based benefit, screening mammography is associated with a high risk false positive tests and may lead to over-diagnosis of clinically insignificant lesions


Oeffinger KC, JAMA 2015  
Myers ER, JAMA, 2015

# Computer aided Detection (CAD)


- Acts as an automated second reader by marking potentially suspicious spots for radiologists to review
- Now used in over 90% of mammograms in the US
- Does not improve diagnostic accuracy of mammography due to many false positives

Lehman, et al, JAMA 2015

- Traditional CAD and AI-based CAD



- Traditional CAD and AI-based CAD



- **Traditional approach**

- learns from being programmed with rules
- for a given task, examples are provided in the form of inputs (called features) and outputs (called labels)

- **Machine learning approach**

- learns from examples
- from observation, computers then determine how to perform the mapping from features to labels in order to create a model that will generalize the information such that a task can be performed
- to find statistical patterns: millions of features and examples are needed.

Powerful computer algorithm is needed to learn massive amounts of data.

**Can computing program based on machine learning can generate certain algorithm to diagnose breast cancer with mammography?**

**Feasibility Test**

# Materials and Methods

- Five hospitals in Korea: consortium for imaging database
- Inclusion
  - Women with 4 views of digital mammograms
- Exclusion
  - Women with surgery for breast cancer
  - Women with surgery for benign disease within 2 years
  - Women with breast cancer undergoing neoadjuvant chemotherapy
  - Women with mammoplastic bag
  - Women with mammographic clip or marker



# Materials and Methods

- 29,107 digital mammogram sets from five institutions
  - Cancer: **4,339** biopsy proven cancers
  - Normal: **24,768** BIRADS category 1 without developing malignancy for 2 years
  - Benign cases were not included.


Normal cases

**N=24,768**


Cancer cases

**N=4,339**

## Normal cases




# Deep Convolutional Neural Network




with Lunit company

# Results

	Sensitivity (%)	Specificity(%)	Accuracy(%)	AUC
<b>Validation Set (n=1238)</b>	75.6 (468/619)	90.2 (558/619)	82.9 (1026/1238)	0.903
<b>Test Set(n=1238)</b>	76.1 (471/619)	88.5 (548/619)	82.3 (1019/1238)	0.906




presented at 2016 RSNA




**F/73**  
**Grade A pattern**

**Invasive ductal carcinoma, Rt**

**Mass, 20mm**




**TP**




**F/43**  
**Grade D pattern**

**Invasive ductal carcinoma, Lt**

**Mass, 11mm**




**TP**



**F/51**  
**Grade D pattern**

**Invasive ductal carcinoma, Lt**

**Mass with microcalcifications, 10mm**



**TP**  
**FP**





OPEN

## Applying Data-driven Imaging Biomarker in Mammography for Breast Cancer Screening: Preliminary Study

Received: 20 June 2017

Accepted: 1 February 2018

Published online: 09 February 2018

Eun-Kyung Kim<sup>1</sup>, Hyo-Eun Kim<sup>2</sup>, Kyunghwa Han<sup>1</sup>, Bong Joo Kang<sup>3</sup>, Yu-Mee Sohn<sup>4</sup>, Ok Hee Woo<sup>5</sup> & Chan Wha Lee<sup>6</sup>

We assessed the feasibility of a data-driven imaging biomarker based on weakly supervised learning (DIB; an imaging biomarker derived from large-scale medical image data with deep learning technology) in mammography (DIB-MG). A total of 29,107 digital mammograms from five institutions (4,339 cancer cases and 24,768 normal cases) were included. After matching patients' age, breast density, and equipment, 1,238 and 1,238 cases were chosen as validation and test sets, respectively, and the remainder were used for training. The core algorithm of DIB-MG is a deep convolutional neural network; a deep learning algorithm specialized for images. Each sample (case) is an exam composed of 4-view images (RCC, RML0, LCC, and LML0). For each case in a training set, the cancer probability inferred from DIB-MG is compared with the per-case ground-truth label. Then the model parameters in DIB-MG are updated based on the error between the prediction and the ground-truth. At the operating point (threshold) of 0.5, sensitivity was 75.6% and 76.1% when specificity was 90.2% and 88.5%, and AUC was 0.903 and 0.906 for the validation and test sets, respectively. This research showed the potential of DIB-MG as a screening tool for breast cancer.

**This is the first study of applying deep learning algorithms in mammography without pixel level supervision.**

The performance was not satisfactory enough, but this research showed the potential of deep learning based mammography CAD as a screening tool for breast cancer and became the driving force for the next study.

## Further study

- Including benign cases
- Per breast malignant risk


# Materials and Methods

- 87,548 mammograms from two university hospitals (2007~2016)
  - Training (YUHS+AMC): in 2007~2010, 2012~2016
  - Validation (YUHS): in 2011 / Test (AMC): in 2011
- Inclusion
  - Screening and Diagnostic 4 views of digital mammograms
- Exclusion
  - Women with surgery for breast cancer
  - Women with breast cancer undergoing neoadjuvant chemotherapy
  - Women with mammoplastic bag

- Cancer: biopsy-proven malignancy
- Normal: BIRADS category 1: negative findings without developing malignancy for 1 year
- Benign: non-cancer with BIRADS category 0,2,3,4,5 with bx proven benign, or showing stability for at least 1yr


# Dataset

Total cases (n=87548)



■ cancer ■ normal ■ benign


Distribution of Cases in Data Set



Training Set Validation Set Test Set


■ Cancer ■ Normal ■ Benign

[stage-1] patch-level training




*n: normal, b: benign, c: cancer*

[stage-2] part-1: main layers



[stage-2] part-2: auxiliary layers



# Result

	<b>Sensitivity (%)</b>	<b>Specificity(%)</b>	<b>Accuracy(%)</b>	<b>AUC</b>
<b>Validation and Test set (N=5664)</b>	82.6 (872/1056)	93.3 (4298/4608)	91.3 (5170/5664)	0.940

presented at 2017 RSNA

	<b>Sensitivity (%)</b>	<b>Specificity(%)</b>	<b>Accuracy(%)</b>	<b>AUC</b>
Test Set (n=1238)	76.1 (471/619)	88.5 (548/619)	82.3 (1019/1238)	0.906

presented at 2016 RSNA

Kim EK, et al. Scientific Reports 2018

# Result

	Fatty breast	Dense breast	p-value*
Sensitivity (%)	81.1 (202/249)	82.7 (632/764)	0.566
Specificity (%)	95.2 (875/919)	92.8 (3157/3402)	0.009
Accuracy (%)	92.2 (1077/1168)	91.0 (3789/4166)	0.179
AUC	0.945	0.939	0.577

\*Chi-square test

We suggest it is possible because the algorithms have learned and trained with large amount of dense breast data





Run DIB

10%

+ Pan


Adjust

Flip

Invert

Reset


RCC



Zoom  
0.34

WW/WL  
894/2093


LCC



Zoom  
0.34

WW/WL  
932/2029


RML0



Zoom  
0.31

WW/WL  
872/2319

LML0



Zoom  
0.31

WW/WL  
926/2277



Run DIB

10%

Anomaly Score (R/L) 3.85% / 99.97%

+ Pan

Adjust

Flip

Invert

Reset

RCC

LCC

RMLO





LMLO

TN

Rt: 5.85%

Lt: 99.85%

TP



Zoom  
0.34

WW/MWL  
894/2093

Zoom  
0.34





WW/MWL  
932/2029




Zoom  
0.31

WW/MWL  
872/2319

Zoom  
0.31

WW/MWL  
926/2277







Run DIB

10%



+ Pan



Adjust

Flip

Invert

Reset







Run DIB

10%




Pan

Adjust




Flip

Invert

Reset













Run DIB 10%

+ Pan Adjust Flip Invert Reset







Run DIB

10%


+ Pan

Adjust

Flip

Invert

Reset





Run DIB

10%

Abnormality Score (Rt): 9.25% / 2.76%

+ Pan

Adjust


Flip

Invert

Reset

RCC

TN




Zoom  
0.34

WW/WL  
900/2527

LCC

Rt: 9.25%




Zoom  
0.34

WW/WL  
900/2551

RMLO

Lt: 2.76%




Zoom  
0.34

WW/WL  
900/2431

LMLO

TN



Zoom  
0.34

WW/WL  
900/2485



Run DIB

10%


+ Pan



Adjust

Flip

Invert


Reset






- From this research we confirmed the potential of AI-based mammography CAD as a screening tool for breast cancer.
- Adding more cases from western countries is needed for this system to be used world widely
- Should prove how much improvement of radiologists' performance with AI

# 170,230 digital mammograms



■ cancer ■ normal ■ benign





- Developed final version of AI-based CAD for mammography “Lunit INSIGHT for Mammography”


Lunit

홈 회사 소개 ▾ 제품소개 ▾ 테크놀로지 ▾ 채용 문의 KO | EN

Lunit INSIGHT  
for Mammography

체험하기

% of malignancy  
each breast with  
heat map



<https://lunit.io>







# Multi-Center Reader Study

- To assess feasibility of artificial intelligence (AI) based diagnostic-support software whether it can be used to improve radiologists' diagnostic performance in terms of cancer detection and false-positive recall in breast cancer screening.
- Total **320 exams** of screening mammograms
  - 160 cancer, 60 benign, 100 normal exams
- **14 readers** (7 general radiologists & 7 special radiologists)
  - Read each case without and then with aid of AI based CAD (Lunit Insight for mammography)
- The difference of readers' decision without and with AI in terms of likelihood-of-malignancy and recall-ness (recall or not) was analyzed.

# Likely of malignancy

	AUC			
	Without AI	With AI	difference	P value
All (n=14)	0.809897	0.880525	0.0706	<0.0001
Specialist (n=7)	0.847294	0.892492	0.0452	<0.0001
General (n=7)	0.772500	0.868557	0.0961	<0.0001

# Cancer Detection and False Positive


	Cancer Detection (%)		False positive (%)	
	Without AI	With AI	Without AI	With AI
All (n=14)	75.27	 84.78	28.11	 25.36
Specialist (n=7)	80.00	 86.34	27.68	 26.25
General (n=7)	70.54	 83.22	28.39	 24.26

RCC

LCC

RMLO

LMLO



Zoom  
0.14  
WW/WL  
4096/2047

Zoom  
0.14  
WW/WL  
4096/2047

Zoom  
0.14  
WW/WL  
4096/2047

Zoom  
0.14  
WW/WL  
4096/2047



9/14 missed

Lunit INSIGHT for Mammography

hekim

RCC LCC RMLO LMLO

CONTROL

- Pan
- Adjust
- Invert
- Flip
- Magnify
- Reset

ABNORMALITY SCORE

RCC/RMLO

High 75%

0 100

LCC/LMLO

Low 0%

0 100

INSIGHT ANALYSIS

Analysis Result

Download Result

Upload DICOM files

Zoom 0.14 WW/WL 4096/2047

Zoom 0.14 WW/WL 4096/2047

Zoom 0.14 WW/WL 4096/2047

Zoom 0.14 WW/WL 4096/2047

Low High

Powered by Lunit Inc. 2018 Product Label

9/14 missed → 2/14 missed

RCC

LCC RMLO





LMLO

[RCC]

[LCC]

[RMLO]

[LMLO]



Zoom  
0.14

WW/WL  
4096/2047

Zoom  
0.14

WW/WL  
4096/2047

Zoom  
0.14

WW/WL  
4096/2047

Zoom  
0.14

WW/WL  
4096/2047




7/14 missed



9/14 missed → 1/14 missed





3/14 false positive

Lunit INSIGHT for Mammography

hekim

RCC LCC RMLO LMLO

CONTROL

- Pan
- Adjust
- Invert
- Flip
- Magnify
- Reset

ABNORMALITY SCORE

RCC/RMLO

Low 1%

0 100

LCC/LMLO

Low 3%

0 100

INSIGHT ANALYSIS

Analysis Result

Download Result

Upload DICOM files

Zoom 0.14 WW/WL 4096/2047


Zoom 0.14 WW/WL 4096/2047

Zoom 0.14 WW/WL 4096/2047


Zoom 0.14 WW/WL 4096/2047

Powered by Lunit Inc. 2018 ProductLabel

3/14 false positive → 2/14 false positive



3/14 false positive



3/14 false positive → 2/14 false positive

- This reader study showed a statistically significant improvement of diagnostic performance with AI.
- Cancer detection rate was increased by 12.6% and false-positive recall rate was decreased by 9.6% with assistance of AI-based diagnostic-support software.
- AI-based diagnostic-support software can be practically used in breast cancer screening.

# Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System

---

*Alejandro Rodríguez-Ruiz, MSc • Elizabeth Krupinski, PhD • Jan-Jurre Mordang, MSc • Kathy Schilling, MD •  
Sylvia H. Heywang-Köbrunner, MD, PhD • Ioannis Sechopoulos, PhD • Ritse M. Mann, MD, PhD*

- AI-based CAD (Trasnspara)
- Total **240 exams** of screening mammograms
- **14 readers** (MQSA qualified)
  - Read each case without and then with aid of AI based CAD

Radiology, 2019

- On average, the AUC was higher with AI support than with unaided reading (0.89 vs 0.87, respectively;  $P = .002$ ).
- Sensitivity increased with AI support (86% vs 83%;  $P = .046$ ), whereas specificity trended toward improvement (79% vs 77%  $P = .06$ ).
- Reading time per case was similar (unaided, 146 seconds; supported by AI, 149 seconds;  $P = .15$ ).
- The AUC with the AI system alone was similar to the average AUC of the radiologists (0.89 vs 0.87).

# Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists

Alejandro Rodriguez-Ruiz, Kristina Lång, Albert Gubern-Merida, Mireille Broeders, Gisella Gennaro, Paola Clauser, Thomas H. Helbich, Margarita Chevalier, Tao Tan, Thomas Mertelmeier, Matthew G. Wallis, Ingvar Andersson, Sophia Zackrisson, Ritse M. Mann, Ioannis Sechopoulos

- The AI system had a 0.840 AUC and the average of the radiologists was 0.814 AUC.
- The performance of the AI system was statistically noninferior to that of the average of the 101 radiologists.

J of Natl Cancer Inst, 2019



- The evaluated AI system achieved a cancer detection accuracy comparable to an average breast radiologist in this retrospective setting.
- Although promising, the performance and impact of such a system in real screening setting needs further investigation.

# Summary

- The AI system for mammography: ready for clinically use
- Studies within a screening scenario should be performed to validate them and seize the real effect of AI support in screening
- We as a clinician should pay more attention to whether this research is going well in the right direction.



YONSEI UNIVERSITY  
COLLEGE OF MEDICINE



**THANK YOU**

